Currently, there are no effective drugs for the treatment of lung infections caused by Mycobacterium abscessus (Mab), a pathogen that causes dangerous infections in people with cystic fibrosis (CF). Therefore, the identification of new drugs against this pathogen is urgently needed.

Thanks to previous projects (FFC#19/2018, FFC#14/2020, FFC#18/2021 and FFC#9/2023), the research group has identified the compound VOMG, which is active against Mab and other pathogens in vitro and in vivo and against biofilm. VOMG acts by blocking cell division through inhibition of the FtsZ protein, which is involved in the division process. Additionally, VOMG is water-soluble, a property that enhances its bioavailability and reduces potential side effects.

VOMG has been patented in co-ownership with FFC Ricerca, and the results obtained so far indicate that it possesses the characteristics of a promising drug candidate against Mab. A second patent has recently been filed, also in co-ownership with FFC Ricerca, covering the use of VOMG in individuals with cystic fibrosis.

This project aims to improve both the delivery and intracellular activity of VOMG through encapsulation in liposomes, lipid-based “shuttle” particles. This new formulation could enhance pulmonary bioavailability and reach intracellular bacteria that are often difficult to eradicate with conventional antibiotics.

The mechanism of action of VOMG will be further investigated using microbiological and biochemical methods. Finally, the activity of VOMG-encapsulating liposome will be tested through several ex vivo assays and in an animal model of chronic Mab infection.

The results could pave the way for the development of novel antimicrobial treatments against Mycobacterium abscessus infections, particularly in people with cystic fibrosis.